Form 4: Nuvation Bio Inc. Director Acquires Stock Options
SEC Form 4 Filing
Robert B. Bazemore, a director of Nuvation Bio Inc., reports the acquisition of stock options.
Summary
- On September 3, 2024, Robert B. Bazemore, a director of Nuvation Bio Inc. [NUVB], acquired 200,801 stock options with an exercise price of $2.98.
- These options vest on the earlier of the one-year anniversary of the grant date (September 3, 2024) or the next shareholder annual meeting, contingent upon continuous service.
- Following the transaction, Bazemore directly owns 200,801 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of earliest transaction: Grant date of stock options. |
| 09/03/2024 | Vesting start date: One-year anniversary of the grant date. |
| 09/02/2034 | Expiration date of the stock options. |
| 09/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.